Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2019

01-08-2019 | Lymphoma | Guide Line

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)

Author: Ken Ohmachi

Published in: International Journal of Hematology | Issue 2/2019

Login to get access

Excerpt

Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) as defined in the 2017 WHO classification [1] accounts for over 30% of all non-Hodgkin lymphomas (NHL) in Japan [2], making it the most prevalent form of NHL. DLBCL can occur as primary disease or through histologic transformation from other low-grade B-cell lymphoma, and is an inhomogeneous group of various entities. It can be classified into subtypes of germinal center B-cell lymphoma and active B-cell/non-germinal center B-cell lymphoma based on cell origin determined by immunohistochemical staining for markers such as CD10, BCL6, and IRF4/MUM1 [3]. However, treatment stratification by subtype is currently only performed in clinical trials. …
Metadata
Title
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)
Author
Ken Ohmachi
Publication date
01-08-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02681-3

Other articles of this Issue 2/2019

International Journal of Hematology 2/2019 Go to the issue

Letter to the Editor

Macrophage elimination in bone marrow by dexamethasone palmitate is associated with successful engraftment in patients with hemophagocytic syndrome

Original Article

The current state of human immunodeficiency virus-associated lymphoma in Japan: a nationwide retrospective study of the Japanese Society of Hematology Blood Disease Registry

Images in Hematology

Detection of Jordans’ anomaly using compact-type automated hematology analyzer

Case Report

Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series

Original Article

Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma

Original Article

Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits